Get your first 3 months of STAT+ for $20
To mark this year's World CRISPR Day, we're offering unlimited access to STAT for $20 for your first three months.
Choose an offer:
Cancel anytime
Monthly Plan
Individual
Best offer
$19
Renews at $39/month
Unlock STAT’s premium subscriber benefits:
Unlock stories from behind the paywall
Gain unlimited access to STAT’s archive of articles — nearly 10 years of invaluable research, reference, and emerging trend tracking.
Discover the news before anyone else
Stay informed with news and insights from the nation's most trusted and well-connected health care, business, and financial journalists.
Access subscriber-only newsletters
Exclusive subscriber-only newsletters are delivered to your inbox daily with in-depth commentary on the latest trends and discoveries.
Meet industry leaders
Unlock discounts and subscriber-only access to STAT’s award-winning Summits and over a dozen other in-person and virtual events.
And make data-driven decisions
Access premium data tools and industry trackers to identify trends, study competitors, and dive deeper into subjects that matter to you.
Frequently Asked Questions
What is STAT+?
STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
Can I purchase a Group subscription for my team?
If you are interested in discounted access for a smaller group or team, get started with a group of 2 to 10 members today. If you are interested in access for a group 11+ or larger, get started with an Enterprise subscription today.
I think I already have access through my institution. How do I find out?
If you believe you already have access to STAT+ and need help getting started, just email us at groups@statnews.com.
Check out our most recent STAT+ stories
Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
Read more